To include your compound in the COVID-19 Resource Center, submit it here.

FDA reviewing Gilead's NDA for HIV triple therapy

Gilead Sciences Inc. (NASDAQ:GILD) said FDA accepted and granted Priority Review to an NDA for bictegravir/emtricitabine/tenofovir

Read the full 164 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE